Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening

References

• Alzheimer’s Disease International. Alzheimer’s disease International. World Alzheimer Report 2018. The state of the art of dementia research: new frontiers. London: Alzheimer’s Disease International; 2018.
   Google Scholar
• Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med 2012;2:a006148.
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237–9.
   PubMed Web of Science ®Google Scholar
• Moya-Alvarado G, Gershoni-Emek N, Perlson E, Bronfman FC. Neurodegeneration and Alzheimer's disease (AD). What can proteomics tell us about the Alzheimer's brain? Mol Cell Proteomics 2016;15:409–25.
   PubMed Web of Science ®Google Scholar
• Prasansuklab A, Tencomnao T. Amyloidosis in Alzheimer's disease: the toxicity of amyloid beta (A beta), mechanisms of its accumulation and implications of medicinal plants for therapy. Evid Based Complement Alternat Med 2013;2013:1.
   Web of Science ®Google Scholar
• Tonnies E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer's disease. J Alzheimers Dis 2017;57:1105–21.
   PubMed Web of Science ®Google Scholar
• Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer's disease: targeting the cholinergic system. Curr Neuropharmacol 2016;14:101–15.
   PubMed Web of Science ®Google Scholar
• Ozgun DO, Yamali C, Gul HI, et al. Inhibitory effects of isatin Mannich bases on carbonic anhydrases, acetylcholinesterase, and butyrylcholinesterase. J Enzyme Inhib Med Chem 2016;31:1498–501.
   PubMed Web of Science ®Google Scholar
• Gülçin İ, Scozzafava A, Supuran CT, et al. The effect of caffeic acid phenethyl ester (CAPE) on metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione S-transferase, lactoperoxidase, and carbonic anhydrase isoenzymes I, II, IX, and XII. J Enzyme Inhib Med Chem 2016;31:1095–101.
   PubMed Web of Science ®Google Scholar
• Woolf NJ, Butcher LL. Cholinergic systems mediate action from movement to higher consciousness. Behav Brain Res 2011;221:488–98.
   PubMed Web of Science ®Google Scholar
• Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184–90.
   PubMed Web of Science ®Google Scholar
• Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999;22:273–80.
   PubMed Web of Science ®Google Scholar
• Bazelyansky M, Robey E, Kirsch JF. Fractional diffusion-limited component of reactions catalyzed by acetylcholinesterase. Biochemistry 1986;25:125–30.
   PubMed Web of Science ®Google Scholar
• Massoulie J, Pezzementi L, Bon S, et al. Molecular and cellular biology of cholinesterases. Prog Neurobiol 1993;41:31–91.
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Forsberg A, Modiri N, et al. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging 2011;32:2320.e15–32.
   Web of Science ®Google Scholar
• Mushtaq G, Greig NH, Khan JA, Kamal MA. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014;13:1432–9.
   PubMed Web of Science ®Google Scholar
• Lane RG, Potkin S, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006;9:101–24.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399:A23–31.
   PubMed Web of Science ®Google Scholar
• Li Q, Yang H, Chen Y, Sun H. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. Eur J Med Chem 2017;132:294–309.
   PubMed Web of Science ®Google Scholar
• Sujayev A, Garibov E, Taslimi P, et al. Synthesis of some tetrahydropyrimidine-5-carboxylates, determination of their metal chelating effects and inhibition profiles against acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase. J Enzyme Inhib Med Chem 2016;31:1531–9.
   PubMed Web of Science ®Google Scholar
• Turan B, Şendil K, Şengül E, et al. The synthesis of some β-lactams and investigation of their metal-chelating activity, carbonic anhydrase and acetylcholinesterase inhibition. J Enzyme Inhib Med Chem 2016;31:79–88.
   PubMed Web of Science ®Google Scholar
• Stahl SM. The new cholinesterase inhibitors for Alzheimer's disease, part 2: illustrating their mechanisms of action. J Clin Psychiatry 2000;61:813–4.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Wright DE, Counsell CE, Zajicek J. Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: a review. Int Psychogeriatr 2012;24:689–97.
   PubMed Web of Science ®Google Scholar
• Macdonald IR, Rockwood K, Martin E, Darvesh S. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? J Alzheimers Dis 2014;42:379–84.
   PubMed Web of Science ®Google Scholar
• Prvulovic D, Schneider B. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease. Expert Opin Drug Metab Toxicol 2014;10:1039–50.
   PubMed Web of Science ®Google Scholar
• Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2015;4:Cd001191.
   Google Scholar
• Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2002;4:Cd001747.
   Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:Cd005593.
   PubMed Web of Science ®Google Scholar
• Brus B, Kosak U, Turk S, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem 2014;57:8167–79.
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE). Chemical Computing Group. Montreal, Canada 2016. Available from: http://www.chemcomp.com,
   Google Scholar
• Halgren TA. Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J Comput Chem 1996;17:616–41.
   Web of Science ®Google Scholar
• Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 2013;27:221–34.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615–23.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Takaoka Y, Endo Y, Yamanobe S, et al. Development of a method for evaluating drug-likeness and ease of synthesis using a data set in which compounds are assigned scores based on chemists' intuition. J Chem Inform Comput Sci 2003;43:1269–75.
   PubMedGoogle Scholar
• Ellman GL, Courtney KD, Andres V, Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Atatreh N, Ghattas MA, Bardaweel SK, et al. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening. Drug Des Devel Ther 2018;12:3741–52.
   PubMed Web of Science ®Google Scholar
• Bajda M, Więckowska A, Hebda M, et al. Structure-based search for new inhibitors of cholinesterases. Int J Mol Sci 2013;14:5608–32.
   PubMed Web of Science ®Google Scholar
• Dighe SN, Deora GS, De la Mora E, et al. Discovery and structure-activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. J Med Chem 2016;59:7683–9.
   PubMed Web of Science ®Google Scholar
• Jin H. Acetylcholinesterase and butyrylcholinesterase inhibitory properties of functionalized tetrahydroacridines and related analogs. 2014;4: 688–96.
   Google Scholar